Bristol-Myers Squibb Company

Bristol-Myers Squibb Company
430 E. 29th Street, 14th Floor,
New York, NY 10016
Phone: 1-800-332-2056Website: https://www.bms.com/Careers: www.bms.com/careers/Pages/home.aspxPatient Assistance Program: www.bms.com/products/Pages/programs.aspx

Latest news

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
28 August 2023
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
16 August 2023
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
30 May 2023
OncoSec presents encouraging early data with TAVO-EP combined with Opdivo in neoadjuvant melanoma
15 November 2022
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
10 September 2022
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
9 September 2022
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
27 July 2022
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
24 June 2022
Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
1 June 2022
U.S. Food and Drug Administration Approves Two Opdivo (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
30 May 2022

Drugs Associated with Bristol-Myers Squibb Company

Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 36 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Brand/Generic Name	Reviews	Rating
Abecma Generic name: idecabtagene vicleucel Drug class: miscellaneous antineoplastics
Abraxane Generic name: paclitaxel protein-bound Drug class: mitotic inhibitors	5 reviews	6.2 / 10
Atripla Generic name: efavirenz/emtricitabine/tenofovir Drug class: antiviral combinations	99 reviews	9.1 / 10
Azactam Generic name: aztreonam Drug class: miscellaneous antibiotics
Baraclude Generic name: entecavir Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)	1 review	10 / 10
Breyanzi Generic name: lisocabtagene maraleucel Drug class: miscellaneous antineoplastics
Camzyos Generic name: mavacamten Drug class: miscellaneous cardiovascular agents
Coumadin Generic name: warfarin Drug class: coumarins and indandiones	21 reviews	8.9 / 10
Droxia Generic name: hydroxyurea Drug class: antimetabolites
Eliquis Generic name: apixaban Drug class: factor Xa inhibitors	191 reviews	4.9 / 10
Empliciti Generic name: elotuzumab Drug class: miscellaneous antineoplastics
Etopophos Generic name: etoposide Drug class: mitotic inhibitors
Evotaz Generic name: atazanavir/cobicistat Drug class: antiviral combinations
Hydrea Generic name: hydroxyurea Drug class: antimetabolites	8 reviews	7.2 / 10
Idhifa Generic name: enasidenib Drug class: miscellaneous antineoplastics
Inrebic Generic name: fedratinib Drug class: multikinase inhibitors
Istodax Generic name: romidepsin Drug class: histone deacetylase inhibitors	1 review	1.0 / 10
Kenalog Generic name: triamcinolone Drug class: topical steroids	29 reviews	8.3 / 10
Lysodren Generic name: mitotane Drug class: miscellaneous antineoplastics
Nulojix Generic name: belatacept Drug class: selective immunosuppressants	1 review	10 / 10
Onureg Generic name: azacitidine Drug class: miscellaneous antineoplastics
Opdivo Generic name: nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)	68 reviews	4.8 / 10
Opdualag Generic name: nivolumab/relatlimab Drug class: antineoplastic combinations
Orencia Generic name: abatacept Drug class: antirheumatics, selective immunosuppressants	64 reviews	5.9 / 10
Plavix Generic name: clopidogrel Drug class: platelet aggregation inhibitors	52 reviews	7.3 / 10
Pomalyst Generic name: pomalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	3 reviews	10 / 10
Reblozyl Generic name: luspatercept Drug class: miscellaneous erythropoiesis agents	2 reviews	10 / 10
Revlimid Generic name: lenalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	18 reviews	6.9 / 10
Reyataz Generic name: atazanavir Drug class: protease inhibitors	3 reviews	8.3 / 10
Sotyktu Generic name: deucravacitinib Drug class: multikinase inhibitors	5 reviews	3.6 / 10
Sprycel Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors	21 reviews	7.5 / 10
Sustiva Generic name: efavirenz Drug class: NNRTIs	6 reviews	5.2 / 10
Thalomid Generic name: thalidomide Drug class: leprostatics, miscellaneous antineoplastics, other immunosuppressants
Vidaza Generic name: azacitidine Drug class: miscellaneous antineoplastics	14 reviews	5.9 / 10
Yervoy Generic name: ipilimumab Drug class: anti-CTLA-4 monoclonal antibodies	2 reviews	9.5 / 10
Zeposia Generic name: ozanimod Drug class: selective immunosuppressants	4 reviews	7.5 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

Discontinued Drugs

Brand/Generic Name	Reviews	Rating
Glucophage Generic name: metformin Drug class: non-sulfonylureas	38 reviews	6.9 / 10
Glucophage XR Generic name: metformin Drug class: non-sulfonylureas	10 reviews	7.8 / 10
Pravachol Generic name: pravastatin Drug class: statins	11 reviews	6.4 / 10
Videx Generic name: didanosine Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Videx EC Generic name: didanosine Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).